Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study Fowler, N., Sharman, J., Smith, S. M., Boyd, T., Grant, B., Kolibaba, K. S., Furman, R. R., Buggy, J., Loury, D., Hamdy, A., Advani, R. AMER SOC HEMATOLOGY. 2010: 425
View details for Web of Science ID 000289662201067